TScan Therapeutics, Inc. - Common Stock (TCRX)

Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

TScan Therapeutics' stock rises after announcing a $30 million financing deal with Lynx1, extending its cash runway into 2027.

TCRX stock results show that TScan Therapeutics met analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

TCRX stock results show that TScan Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.

Although lesser-known ideas present high risks, these cheap stocks under $10 could be intriguing for the calculating speculator.

TCRX stock results show that TScan Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.